Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome p450 3a: A bioinformatic and animal study

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 2555-2602

  Su, Junhui ^a,b,c   Chang, Cui ^c   Xiang, Qi ^a,b   Zhou, Zhi Wei ^d   Luo, Rong ^e   Yang, Lun ^f   He, Zhi Xu ^g   Yang, Hongtu ^b,c   Li, Jianan ^a   Bei, Yu ^a   Xu, Jinmei ^a,b   Zhang, Minjing ^a   Zhang, Qihao ^a   Su, Zhijian ^a   Huang, Yadong ^a   Pang, Jiyan ^e   Zhou, Shu Feng ^d,g  

^a Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine   (China)

^b JINAN UNIVERSITY   (China)

^c SHENZHEN PEOPLE'S HOSPITAL   (China)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e SUN YAT SEN UNIVERSITY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY   (China)

^g GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Bioinformatics; Cytochrome P450 3A; DAVID; DDI CPI tool; Midazolam; Molecular target; Pharmacokinetics; Rat; Xyloketal B

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; CYTOCHROME P450 3A2; MIDAZOLAM; NATURAL PRODUCT; UNCLASSIFIED DRUG; XYLOKETAL B; PYRAN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOINFORMATICS; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG INTERACTION; GENE IDENTIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; IN VIVO STUDY; LIVER MICROSOME; MALE; MOLECULAR DOCKING; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMA CLEARANCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RAT; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; XYLARIALES; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGY; BIOSYNTHESIS; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; COMPUTATIONAL BIOLOGY; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; MALE; MIDAZOLAM; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PYRANS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84930477759     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S73476     Document Type: Article

References (57)

1. Ghosh N, Ghosh R, Mandal V, Mandal SC. Recent advances in herbal medicine for treatment of liver diseases. Pharm Biol. 2011;49(9):9709–9788.
2. Haeckel R. Verification, validation and evaluation of analytical procedures in laboratory medicine. Clin Chem Lab Med. 2004;42(1):111–112.
3. Mishra BB, Tiwari VK. Natural products: an evolving role in future drug discovery. Eur J Med Chem. 2011;46(10):4769–4807.
4. International Conference on Harmonisation. Validation of analytical procedures: text and methodology, 2005. Available from: http://www.ich.org/products/guidelines/quality/quality-single/article/validation-of-analytical-procedures-text-and-methodology.html. Accessed October 1, 2014.
5. Wijnen PA, Op den Buijsch RA, Drent M, et al. Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther. 2007;26 Suppl 2:211–219.
6. Denisov IG, Makris TM, Sligar SG, Schlichting I. Structure and chemistry of cytochrome P450. Chem Rev. 2005;105(6):2253–2277.
7. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9(4):310–322.
8. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687–710.
9. Nagata K, Ogino M, Shimada M, Miyata M, Gonzalez FJ, Yamazoe Y. Structure and expression of the rat CYP3A1 gene: isolation of the gene (P450/6βB) and characterization of the recombinant protein. Arch Biochem Biophys. 1999;362(2):242–253.
10. Dai D, Bai R, Hodgson E, Rose RL. Cloning, sequencing, heterologous expression, and characterization of murine cytochrome P450 3a25*(Cyp3a25), a testosterone 6β-hydroxylase. J Biochem Mol Toxicol. 2001;15(2):90–99.
11. World Health Organization. Global status report on oncommunicable diseases 2010. Geneva, Switzerland: World Health Organization; 2011. Available from: http://www.who.int/nmh/publications/ncd_report_full_en.pdf. Accessed September 26, 2014.
12. World Health Organization. Global atlas on cardiovascular disease prevention and control. Geneva, Switzerland: World Health Organization; 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241564373_eng.pdf. Accessed September 26, 2014.
13. Hamilton CA, Miller WH, Al-Benna S, et al. Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci (Lond). 2004;106(3):219–234.
14. Sachidanandam K, Fagan SC, Ergul A. Oxidative stress and cardiovascular disease: antioxidants and unresolved issues. Cardiovasc Drug Rev. 2005;23(2):115–132.
15. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75(3):311–335.
16. Kuete V, Efferth T. Cameroonian medicinal plants: pharmacology and derived natural products. Front Pharmacol. 2010;1:123.
17. Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR. Marine natural products. Nat Prod Rep. 2012;29(2):144.
18. Jha RK, Zi-Rong X. Biomedical compounds from marine organisms. Mar Drugs. 2004;2(3):123–146.
19. Handa K, Nakagome I, Yamaotsu N, Gouda H, Hirono S. Three-dimensional quantitative structure-activity relationship analysis of inhibitors of human and rat cytochrome P4503A enzymes. Drug Metab Pharmacokinet. 2013;28(4):345–355.
20. Pettigrew JD, Wilson PD. Synthesis of xyloketal A, B, C, D, and G analogues. J Org Chem. 2006;71(4):1620–1625.
21. Wu XY, Liu XH, Lin YC, et al. Xyloketal F: a strong L-calcium channel blocker from the mangrove fungus Xylaria sp.(# 2508) from the South China Sea coast. Eur J Org Chem. 2005;2005(19):4061–4064.
22. Zhang W, Liu Y, Yang H, et al. A validated high-performance liquid chromatographic method with diode-array detection for the estimation of xyloketal B in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;885–886:24–29.
23. Luo H, Chen J, Shi L, et al. DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res. 2011;39 (Web Server issue):W492–W498.
24. Luo H, Zhang P, Huang H, et al. DDI-CPI, a server that predicts drug-drug interactions through implementing the chemical-protein interactome. Nucleic Acids Res. 2014;42(Web Server issue):W46–W52.
25. Wang R, Fang X, Lu Y, Wang S. The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J Med Chem. 2004;47(12):2977–2980.
26. Yang L, Luo H, Chen J, Xing Q, He L. SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Res. 2009;37(Web Server issue):W406–W412.
27. Yang L, Chen J, Shi L, Hudock MP, Wang K, He L. Identifying unexpected therapeutic targets via chemical-protein interactome. PLoS One. 2010;5(3):e9568.
28. Wang ZX, Sun J, Howell CE, et al. Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. Fundam Clin Pharmacol. 2014;28(5):551–582.
29. Nagata K, Buppodom P, Matsunaga T, et al. Purification and characterization of seven distinct forms of liver microsomal cytochrome P-450 from untreated and inducer-treated male Wistar rats. J Biochem. 1985;97(6):1755–1766.
30. Li WL, Xin HW, Su MW. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat. Basic Clin Pharmacol Toxicol. 2012;110(2):187–192.
31. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99(3):306–314.
32. Zhou ZW, Zhou SF. Application of mechanism-based CYP inhibition for predicting drug-drug interactions. Expert Opin Drug Metab Toxicol. 2009;5(6):579–605.
33. Yamamoto A. A uniqe antilipidemic drug-probucol. J Atheroscler Thromb. 2008;15(6):304–305.
34. Chen WL, Qian Y, Meng WF, et al. A novel marine compound xyloketal B protects against oxidized LDL-induced cell injury in vitro. Biochem Pharmacol. 2009;78(8):941–950.
35. Zhao J, Li L, Ling C, et al. Marine compound Xyloketal B protects PC12 cells against OGD-induced cell damage. Brain Res. 2009;1302:240–247.
36. Lu XL, Yao XL, Liu Z, et al. Protective effects of xyloketal B against MPP+-induced neurotoxicity in Caenorhabditis elegans and PC12 cells. Brain Res. 2010;1332:110–119.
37. Li ZX, Chen JW, Yuan F, et al. Xyloketal B exhibits its antioxidant activity through induction of HO-1 in vascular endothelial cells and zebrafish. Mar Drugs. 2013;11(2):504–522.
38. Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci. 2005;26(5):394–404.
39. Nishino Y, Kubota A, Kanazawa T, Takashima Y, Ozeki T, Okada H. Improved intestinal absorption of a poorly water-soluble oral drug using mannitol microparticles containing a nanosolid drug dispersion. J Pharm Sci. 2012;101(11):4191–4200.
40. Sha X, Wu J, Chen Y, Fang X. Self-microemulsifying drug-delivery system for improved oral bioavailability of probucol: preparation and evaluation. Int J Nanomedicine. 2012;7:705–712.
41. Zhang Z, Huang J, Jiang S, et al. A high-drug-loading self-assembled nanoemulsion enhances the oral absorption of probucol in rats. J Pharm Sci. 2013;102(4):1301–1306.
42. Krupka E, Venisse N, Lafay C, et al. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers. Eur J Clin Pharmacol. 2006;62(8):653–659.
43. Nogawa H, Kawai T, Yajima M, Miura M, Ogawa T, Murakami K. Effects of probucol, a typical hERG expression inhibitor, on in vivo QT interval prolongation in conscious dogs. Eur J Pharmacol. 2013;720(1–3):29–37.
44. Miida T, Seino U, Miyazaki O, et al. Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis. 2008;200(2):329–335.
45. Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH. Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol. 2004;24(12):2345–2350.
46. Yang L, Wang KJ, Wang LS, et al. Chemical-protein interactome and its application in off-target identification. Interdiscip Sci. 2011;3(1):22–30.
47. Yang L, Wang K, Chen J, et al. Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome- clozapine-induced agranulocytosis as a case study. PLoS Comput Biol. 2011;7(3):e1002016.
48. Soucek P, Gut I. Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica. 1992;22(1):83–103.
49. Shin KH, Choi MH, Lim KS, Yu KS, Jang IJ, Cho JY. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin Pharmacol Ther. 2013;94(5):601–609.
50. Yamano K, Yamamoto K, Katashima M, et al. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab Dispos. 2001;29(4 Pt 1):443–452.
51. Hoen PA, Bijsterbosch MK, van Berkel TJ, Vermeulen NP, Commandeur JN. Midazolam is a phenobarbital-like cytochrome p450 inducer in rats. J Pharmacol Exp Ther. 2001;299(3):921–927.
52. Yang J, Liao M, Shou M, et al. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab. 2008;9(5):384–394.
53. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007;8(2):93–103.
54. Hobert O. Gene regulation by transcription factors and microRNAs. Science. 2008;319(5871):1785–1786.
55. Khan AA, Chow EC, van Loenen-Weemaes AM, Porte RJ, Pang KS, Groothuis GM. Comparison of effects of VDR versus PXR, FXR and GR ligands on the regulation of CYP3A isozymes in rat and human intestine and liver. Eur J Pharm Sci. 2009;37(2):115–125.
56. Ni S, Wang X, Wang J, Zeng S, Zhao Z. Expression of CYP3A23/1, CYP3A2, PXR, CAR and HNF4alpha in large-for-gestational-age neonatal rats. Pharmazie. 2009;64(4):252–257.
57. De Martin S, Gabbia D, Albertin G, et al. Differential effect of liver cirrhosis on the PXR-mediated induction of cytochromes P450 3A1 and 3A2 in the rat. Drug Metab Dispos. 2014;42(10):1617–1626.